Dana-Farber Cancer Institute (Boston) ( Site 0007)

Boston, Massachusetts 02215

0 studies enrolling now · 1 studies all time

What they study most

Renal Cell Carcinoma

Studies at this site

• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) — Completed